CN104379753B - 位点特异性整合 - Google Patents

位点特异性整合 Download PDF

Info

Publication number
CN104379753B
CN104379753B CN201380032837.8A CN201380032837A CN104379753B CN 104379753 B CN104379753 B CN 104379753B CN 201380032837 A CN201380032837 A CN 201380032837A CN 104379753 B CN104379753 B CN 104379753B
Authority
CN
China
Prior art keywords
sequence
cell
host cell
gene
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380032837.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104379753A (zh
Inventor
J·朗斯
R·扬
M·J·奥古斯汀诺
M·莫法特
张�林
张保宏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lonza Biologics PLC
Pfizer Corp SRL
Original Assignee
Lonza Biologics PLC
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza Biologics PLC, Pfizer Corp SRL filed Critical Lonza Biologics PLC
Publication of CN104379753A publication Critical patent/CN104379753A/zh
Application granted granted Critical
Publication of CN104379753B publication Critical patent/CN104379753B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201380032837.8A 2012-06-22 2013-06-20 位点特异性整合 Active CN104379753B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261663147P 2012-06-22 2012-06-22
US61/663,147 2012-06-22
EP12185330.3A EP2711428A1 (en) 2012-09-21 2012-09-21 Site-specific integration
EP12185330.3 2012-09-21
PCT/EP2013/062859 WO2013190032A1 (en) 2012-06-22 2013-06-20 Site-specific integration

Publications (2)

Publication Number Publication Date
CN104379753A CN104379753A (zh) 2015-02-25
CN104379753B true CN104379753B (zh) 2020-06-09

Family

ID=46888327

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380032837.8A Active CN104379753B (zh) 2012-06-22 2013-06-20 位点特异性整合

Country Status (18)

Country Link
US (2) US10280436B2 (enExample)
EP (2) EP2711428A1 (enExample)
JP (1) JP6053923B2 (enExample)
KR (1) KR101761709B1 (enExample)
CN (1) CN104379753B (enExample)
AU (1) AU2013279333C1 (enExample)
BR (1) BR112014032299B1 (enExample)
CA (1) CA2876280C (enExample)
DK (1) DK2864489T3 (enExample)
EA (1) EA034039B1 (enExample)
ES (1) ES2629509T3 (enExample)
IL (1) IL236347A0 (enExample)
IN (1) IN2014MN02518A (enExample)
MX (1) MX351727B (enExample)
PL (1) PL2864489T3 (enExample)
SG (1) SG11201408576QA (enExample)
TW (1) TWI523946B (enExample)
WO (1) WO2013190032A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
CN113981027A (zh) * 2015-04-27 2022-01-28 动量制药公司 制备治疗性蛋白质的方法
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
EP3408397B1 (en) 2016-01-27 2020-07-15 Just-Evotec Biologics, Inc. Hybrid promoter and uses thereof
EP3445780A1 (en) * 2016-04-20 2019-02-27 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of an expression-enhancing locus
TWI827531B (zh) * 2016-04-20 2024-01-01 美商再生元醫藥公司 基於使用增強表現基因座之製備抗體的組成物及方法
CA3053712A1 (en) * 2017-02-17 2018-08-23 Lonza Ltd. Multi-site specific integration cells for difficult to express proteins
CA3053304A1 (en) * 2017-02-17 2018-08-23 Lonza Ltd. Mammalian cells for producing adeno-associated viruses
GB201703418D0 (en) * 2017-03-03 2017-04-19 Ge Healthcare Bio Sciences Ab Method for cell line development
CA3056182A1 (en) 2017-03-16 2018-09-20 Pfizer Inc. Tyrosine prototrophy
CN107557390A (zh) * 2017-09-18 2018-01-09 江南大学 一种筛选cho细胞系高表达位点的方法
IL275462B1 (en) * 2017-12-22 2025-09-01 Genentech Inc Targeted integration of nucleic acids
JP7549582B2 (ja) * 2018-10-01 2024-09-11 ロンザ リミテッド 予測可能かつ安定な導入遺伝子発現を有するｓｓｉ細胞および形成の方法
AU2019403279A1 (en) * 2018-12-21 2021-07-01 Genentech, Inc. Targeted integration of nucleic acids
EP3950938A4 (en) * 2019-04-02 2023-01-18 Chugai Seiyaku Kabushiki Kaisha METHOD FOR INTRODUCING A FOREIGN TARGET-SPECIFIC GENE
KR20220097910A (ko) 2019-11-14 2022-07-08 론자 리미티드 세포 선택 방법
KR102335242B1 (ko) 2020-05-22 2021-12-02 인천대학교 산학협력단 Fer1L4 유전자에 부위-특이적 통합된 RMCE 랜딩 패드를 포함하는 CHO 세포
US20230287455A1 (en) 2020-07-30 2023-09-14 Pfizer Inc. Cells Having Gene Duplications and Uses Thereof
JP2024528139A (ja) 2021-08-02 2024-07-26 ファイザー・インク 改良された発現ベクターおよびその使用
AU2022373653A1 (en) 2021-10-18 2024-05-02 Regeneron Pharmaceuticals, Inc. Eukaryotic cells comprising adenovirus-associated virus polynucleotides
WO2023148598A1 (en) 2022-02-02 2023-08-10 Pfizer Inc. Cysteine prototrophy
CN119955730A (zh) * 2023-11-08 2025-05-09 深圳太力生物技术有限责任公司 一种细胞株及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
DE69840439D1 (de) 1997-04-24 2009-02-26 Univ Washington Zielgerichtete genveraenderung mit parvoviralen vektoren
BRPI0513706A (pt) * 2004-07-20 2008-05-13 Symphogen As anticorpo policlonal recombinante anti-rhesus d e métodos de produção
JP4665115B2 (ja) * 2004-08-06 2011-04-06 独立行政法人理化学研究所 骨・関節疾患感受性遺伝子およびその用途
WO2007014275A2 (en) 2005-07-26 2007-02-01 Sangamo Biosciences, Inc. Targeted integration and expression of exogenous nucleic acid sequences

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Characterization of a bipartite recombinant adeno-associated viral vector for site integration;ZHANG C等;《HUMAN GENE THERAPY》;20070930;第18卷(第9期);787-797 *
FLP/FRT 位点特异性重组系统在高等真核生物中的研究进展;赵爱春等;《中国农业科学》;20111231;第44卷(第15期);第3256页左栏倒数第1段-第3257页左栏第2段，及图5 *
基因打靶技术：开启遗传学新纪元;滕艳等;《遗传》;20071231;第29卷(第11期);1291-1298 *

Also Published As

Publication number Publication date
AU2013279333B9 (en) 2017-06-29
US10280436B2 (en) 2019-05-07
US20190119702A1 (en) 2019-04-25
EA201590068A1 (ru) 2015-04-30
TWI523946B (zh) 2016-03-01
CN104379753A (zh) 2015-02-25
BR112014032299B1 (pt) 2021-09-21
EP2711428A1 (en) 2014-03-26
CA2876280C (en) 2018-02-06
MX2014015612A (es) 2015-07-14
SG11201408576QA (en) 2015-03-30
MX351727B (es) 2017-10-26
US20150167020A1 (en) 2015-06-18
EA034039B1 (ru) 2019-12-20
IL236347A0 (en) 2015-02-26
IN2014MN02518A (enExample) 2015-07-17
BR112014032299A2 (pt) 2017-08-01
AU2013279333B2 (en) 2017-03-30
JP6053923B2 (ja) 2016-12-27
WO2013190032A1 (en) 2013-12-27
EP2864489B1 (en) 2017-03-29
ES2629509T3 (es) 2017-08-10
AU2013279333C1 (en) 2017-08-31
KR20150029693A (ko) 2015-03-18
DK2864489T3 (en) 2017-07-17
TW201420762A (zh) 2014-06-01
EP2864489A1 (en) 2015-04-29
US11326185B2 (en) 2022-05-10
PL2864489T3 (pl) 2017-09-29
CA2876280A1 (en) 2013-12-27
HK1202580A1 (en) 2015-10-02
AU2013279333A1 (en) 2015-02-12
KR101761709B1 (ko) 2017-07-26
JP2015519914A (ja) 2015-07-16

Similar Documents

Publication Publication Date Title
CN104379753B (zh) 位点特异性整合
Zhang et al. Recombinase‐mediated cassette exchange (RMCE) for monoclonal antibody expression in the commercially relevant CHOK1SV cell line
JP4489424B2 (ja) 染色体に基くプラットホーム
AU2024220126A1 (en) Compositions and methods for making antibodies based on use of an expression-enhancing locus
AU2017253241B2 (en) Compositions and methods for making antibodies based on use of expression-enhancing loci
TW200914612A (en) Promoter
WO2019096054A1 (zh) 一种筛选谷氨酰胺合成酶缺陷型hek293细胞株的方法
KR20100097123A (ko) 신규한 재조합 서열
JP4568378B2 (ja) 遺伝子発現安定化エレメント
HK1202580B (zh) 位点特异性整合
CN105695509B (zh) 一种获得高纯度心肌细胞的方法
US12503520B2 (en) Compositions and methods for making antibodies based on use of an expression-enhancing locus
EP2058391B1 (en) Method for highly amplifying target gene in mammalian cell and vector therefor
CN120665817A (zh) 一种cho细胞基因nw_023276806.1内稳定表达蛋白质的位点及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Burke, the British town of slough

Applicant after: U.K. Longsha Bio-medical Co., Ltd.

Applicant after: Pfizer Corp.

Address before: Burke, the British town of slough

Applicant before: U.K. Longsha Bio-medical Co., Ltd.

Applicant before: PFIZER INC.

C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1202580

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant